RJA
NKTR icon

Raymond James & Associates’s Nektar Therapeutics NKTR Stock Holding History

Raymond James & Associates’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-953
Closed -$8K – 3546
2017
Q4 		$8K Buy
+953
New +$564K ﹤0.01% 3384

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Raymond James & Associates's NKTR Position: Q4 2022 in Review

Raymond James & Associates sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 667 shares — an estimated $32K sold.

Raymond James & Associates first reported a position in NKTR in Q4 2014 and held it in 32 quarters. The position peaked at $9.79M in Q1 2018. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

  • Raymond James & Associates reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 667 Nektar Therapeutics shares in Q4 2022, an estimated $32K.
  • Raymond James & Associates first reported a position in Nektar Therapeutics in Q4 2014 and held it in 32 quarters.
  • Raymond James & Associates's Nektar Therapeutics position peaked at $9.79M in Q1 2018.
  • 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.